Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Ubrogepant

Alternative Names: ubrogepant, mk-1602, ubrelvy
Latest Update: 2025-03-05
Latest Update Note: Clinical Trial Update

Product Description

Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31800988/)

Mechanisms of Action: CGRP Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Israel | Saudi Arabia | United Arab Emirates | United States

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ubrogepant

Countries in Clinic: Puerto Rico, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Migraine Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
UBRO MM

P3

Recruiting

Migraine Disorders

2027-06-01

Ages 6-17

P3

Enrolling by invitation

Migraine Disorders

2027-05-05

Ubro Peds

P3

Recruiting

Migraine Disorders

2026-05-01

20527A

P1

Recruiting

Migraine Disorders

2025-07-24

Recent News Events

Date

Type

Title

11/14/2024

News Article

 Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

05/08/2024

News Article

 QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults

03/20/2024

News Article

 Deerfield Agency Welcomes Bill Veltre as EVP, Head of Media

11/29/2023

News Article

 Pfizer's Nurtec Receives Top Ranking in 2023 TGaS Digital Marketing Competency Report

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions